Insulet Co. (NASDAQ:PODD) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Insulet Co. (NASDAQ:PODD) have earned an average rating of “Moderate Buy” from the sixteen analysts that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $267.44.

Several analysts have recently issued reports on PODD shares. Raymond James increased their target price on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Citigroup raised their target price on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Barclays boosted their target price on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Sanford C. Bernstein initiated coverage on shares of Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target on the stock. Finally, BTIG Research boosted their price objective on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th.

Insulet Trading Down 2.6 %

Shares of NASDAQ:PODD opened at $256.44 on Thursday. The business’s 50 day simple moving average is $253.30 and its 200 day simple moving average is $222.13. Insulet has a 1 year low of $160.19 and a 1 year high of $279.77. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market capitalization of $17.99 billion, a P/E ratio of 43.91, a P/E/G ratio of 4.12 and a beta of 1.21.

Insider Transactions at Insulet

In other news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.47% of the company’s stock.

Institutional Trading of Insulet

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Baillie Gifford & Co. grew its position in shares of Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after buying an additional 389,639 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Insulet by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after acquiring an additional 22,850 shares during the period. Clearbridge Investments LLC boosted its holdings in Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock valued at $270,364,000 after acquiring an additional 75,526 shares during the last quarter. American Century Companies Inc. increased its position in Insulet by 18.7% during the 2nd quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock valued at $178,728,000 after purchasing an additional 139,246 shares during the period. Finally, Westfield Capital Management Co. LP raised its holdings in Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.